Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B17 | O75795 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29741125 | 0.89 | CYP11B1 (0.37) | CYP11B1CYP11B2 | |
| SCHEMBL16800617 | 0.89 | CYP11B1 (0.37) | CYP11B1CYP11B2 | |
| SCHEMBL16798084 | 0.89 | CYP11B1 (0.37) | CYP11B1CYP11B2 | |
| SCHEMBL6947201 | 0.82 | HTR6 (0.33) | UGT2B17HTR6CYP11B1CYP11B2 | |
| SCHEMBL31127749 | 0.79 | EPAS1 (0.32) | UGT2B17 | |
| SCHEMBL29740991 | 0.79 | UGT2B17 (0.41) | UGT2B17CAMK2A | |
| SCHEMBL28959025 | 0.76 | HTR6 (0.30) | HTR6 | |
| SCHEMBL19534845 | 0.73 | KDM1A (0.30) | — | |
| SCHEMBL13451096 | 0.73 | KDM1A (0.33) | KMT2A | |
| SCHEMBL24593510 | 0.72 | UGT2B17 (0.49) | UGT2B17KMT2ACYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612243-B2 | Cyclopenta[b]naphthalene derivatives | MERCK PATENT GMBH (DE) | 2009-11-03 | — | — | US | disclosed |
| US-7612243-B2 | Cyclopenta[b]naphthalene derivatives | MERCK PATENT GMBH (DE) | 2009-11-03 | — | — | US | disclosed |
| US-20080058537-A1 | CYCLOPENTA[B]NAPHTHALENE DERIVATIVES | LIETZAU LARS | 2008-03-06 | — | — | US | disclosed |
| US-20080058537-A1 | CYCLOPENTA[B]NAPHTHALENE DERIVATIVES | LIETZAU LARS | 2008-03-06 | — | — | US | disclosed |
| US-7291366-B2 | Cyclopenta[b]naphthalene derivatives | MERCK PATENT GMBH (DE) | 2007-11-06 | — | — | US | disclosed |
| US-7291366-B2 | Cyclopenta[b]naphthalene derivatives | MERCK PATENT GMBH (DE) | 2007-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058537-A1 | CYCLOPENTA[B]NAPHTHALENE DERIVATIVES | NUCB2, NDC1, JUP | UGT2B17 2813/4885KMT2A 4706/4885HTR6 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.